ArcticZymes Technologies ASA (OSL: AZT)

Market Cap	673.12M
Revenue (ttm)	110.76M
Net Income (ttm)	4.63M
Shares Out	51.07M
EPS (ttm)	0.08
PE Ratio	155.42
Forward PE	91.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,145
Open	13.14
Previous Close	13.38
Day's Range	13.10 - 13.40
52-Week Range	13.02 - 43.20
Beta	0.95
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2024

About AZT

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing in Norway, Germany, Lithuania, France, Italy, rest of Europe, the United States, and internationally. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays; salt active nuclease for the removal of nucleic acids during man...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1990
• Employees: 61
• Stock Exchange: Oslo Børs
• Ticker Symbol: AZT

Financial Performance

In 2023, AZT's revenue was 119.65 million, a decrease of -13.09% compared to the previous year's 137.67 million. Earnings were 19.43 million, a decrease of -40.89%.